An object of the present invention is to provide a recording material or a recording sheet using, as a color-developing agent, a non-phenol-based compound good in color developing performance and the like. A compound represented by the following formula (I) is used as the color-developing agent: ##STR00001##
(wherein X represents CH.sub.2 or the like; R.sup.1 to R.sup.3 each independently represent a hydrogen atom, a halogen atom or the like; n1 and n3 each independently represent any integer of 1 to 5; two groups represented by R.sup.3 adjacent to each other on a benzene ring optionally bond to each other to form an optionally substituted 6-membered ring; and n2 represents any integer of 1 to 4).

An electrolyte solution additive, a non-aqueous electrolyte solution including the same, and a lithium secondary battery including the same are disclosed herein. In some embodiments, an electrolyte solution additive is represented by Formula 1

##STR00001##

wherein, in Formula 1,

R is a substituted or unsubstituted alkylene group having 1 to 5 carbon atoms.

An electrolyte solution additive, a non-aqueous electrolyte solution including the same, and a lithium secondary battery including the same are disclosed herein. In some embodiments, an electrolyte solution additive is represented by Formula 1

##STR00001##

wherein, in Formula 1,

R is a substituted or unsubstituted alkylene group having 1 to 5 carbon atoms.

The present invention relates to compositions and methods for determining the absolute configuration of D/L-cysteine and/or the enantiomeric composition of cysteine and/or the concentration of total cysteine in a sample. Uses of the composition and method are also described.

The present invention relates to compositions and methods for determining the absolute configuration of D/L-cysteine and/or the enantiomeric composition of cysteine and/or the concentration of total cysteine in a sample. Uses of the composition and method are also described.

The present invention relates to compositions and methods for determining the absolute configuration of D/L-cysteine and/or the enantiomeric composition of cysteine and/or the concentration of total cysteine in a sample. Uses of the composition and method are also described.

The invention relates to an improved process for synthesizing 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide of the formula: ##STR00001## Compound I is currently in clinical trials for the treatment of auto-immune and auto-inflammatory diseases such as psoriasis.

The invention relates to an improved process for synthesizing 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide of the formula: ##STR00001## Compound I is currently in clinical trials for the treatment of auto-immune and auto-inflammatory diseases such as psoriasis.

Subject-matter of the invention is a process for the preparation of a key intermediate in the synthesis of indacaterol. Subject-matter of the invention are also new synthesis intermediates. Formula (I):

##STR00001##

Subject-matter of the invention is a process for the preparation of a key intermediate in the synthesis of indacaterol. Subject-matter of the invention are also new synthesis intermediates. Formula (I):

##STR00001##